Navigation Links
Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model
Date:4/8/2013

CAMBRIDGE, Mass., April 8, 2013 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor sensitivity and delays the onset of resistance to the aromatase inhibitor, letrozole, in an ER+ breast cancer model. The study was presented as part of the American Association for Cancer Research's 2013 Annual Meeting in Washington, DC, April 6-10, 2013.

MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in tumor growth and survival. By inhibiting ErbB3 signaling, MM-121 was found to restore sensitivity, delay resistance and enhance the anti-tumor effect of letrozole as a combination therapy partner.

"In nearly all cases of advanced ER+ breast cancer, endocrine therapies are initially effective, but patients eventually develop resistance to these treatments," said Gavin MacBeath , Co-Founder and Head of Translational Research, Merrimack Pharmaceuticals. "We are excited to see that in preclinical models, MM-121 blocked activation of its target, ErbB3, and down-regulated several signaling pathways within these tumors.  We saw delayed resistance to letrozole when co-administered with the drug, and restored sensitivity when added after the tumors developed resistance to letrozole. These data help guide our thinking regarding how best to combine MM-121 with anti-hormonal therapies in the treatment of advanced ER+ breast cancer."

Study Methodology
The activity of MM-121 alone and in combination with letrozole was measured in an MCF7 in vivo model of post-menopausal ER+ breast cancer engineered to express aromatase. Models of ER+ breast cancer were randomized to receive letrozole, MM-121 or both MM-121 and letrozole following development of resistance to letrozole. Tumor
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
2. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
3. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
6. Vanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Regeneron Pharmaceuticals Announces Expansion in New Yorks Hudson Valley
8. Valeant Pharmaceuticals Provides Update to Recent Event
9. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
10. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Actavis plc (NYSE: ACT ... a complete response letter from the U.S. Food ... Application (NDA) for the fixed-dose combination (FDC) of ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... receipt of a complete response letter, Actavis remains ...
(Date:12/24/2014)... Dec. 24, 2014 Kinex Pharmaceuticals announced today ... at Roswell Park Cancer Institute. KX2-361 (KX02), ... that has shown potent inhibitory activity against a broad ... are resistant to Temozolomide (T98G), the most widely used ... well-established brain tumor mouse model, KX2-361 consistently clears brain ...
(Date:12/24/2014)... Dec. 24, 2014  Conkwest, Inc., the Natural ... proprietary Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) ... Patrick Soon-Shiong , NantWorks founder, physician scientist and ... to purchase approximately $48 million of the Company,s ... investment, he will be named Co-Chairman of the ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... on the Vine Varieties not Subject to Salmonella ... ... brand, and is North America,s largest grower of greenhouse,tomatoes, wants to let consumers ... US are not subject to the most recent June,7, 2008 Salmonella alert issued ...
... ST. LOUIS, June 9 ETHEX Corporation announced today,that ... sulfate 60 mg,extended release tablets (Lot No. 91762) due ... thickness. Oversized tablets may contain as much as,two times ... was,distributed by ETHEX Corporation under an "ETHEX" label between ...
... parasite, a team of researchers has been able to ... has thereby broken the cycle of infection during recent ... parasite through gene knock-out technol-ogy, a research team consisting ... Hopkins University, Baltimore, has prevented the parasite from going ...
... both genders over 25-year period , , MONDAY, June 9 ... arteries work just as well in women as in men, ... recent years, new research finds. , The study in the ... College of Cardiology is a marker in a fading ...
... Sen. Max Baucus,(D-MT), chair of the Senate ... bill that includes pharmacy-related provisions to provide ... claims and delay the,implementation of Medicaid reimbursement ... Roberts, RPh, executive vice president and CEO ...
... ALBANY, Ore., June 9 Synthetech, Inc. (OTC,Bulletin ... 2008 Dr. Gregory R.,Hahn will become Synthetech,s President ... has served as Synthetech,s President and Chief,Operating Officer. ... Dr.,Daniel T. Fagan, who will continue as Synthetech,s ...
Cached Medicine News:Health News:Consumers Can Purchase Majority of Tomato Varieties 2Health News:ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets 2Health News:ETHEX Corporation Voluntarily Recalls a Single Lot of Morphine Sulfate 60 mg Extended Release Tablets Due to the Potential for Oversized Tablets 3Health News:Researchers block transmission of malaria in animal tests 2Health News:Researchers block transmission of malaria in animal tests 3Health News:Artery-Opening Method Works Well in Women 2Health News:Artery-Opening Method Works Well in Women 3Health News:NCPA Statement on Sen. Baucus' Medicare Bill Inclusion of Solutions for Medicare and Medicaid Reimbursement Problems 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 2Health News:Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: